On May 26, 2023, Marinus Pharmaceuticals announced that its drug, ZTALMY (ganaxolone) oral suspension, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). ZTALMY is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age, and may be continued in patients aged 18 and over. CDD is a genetic disease that causes seizures in early childhood. If approved, ZTALMY will be the first treatment in the EU indicated for the adjunctive treatment of seizures associated with CDD. The CHMP recommendation will now be reviewed by the European Commission (EC), which has the power to approve medicines for the European Union (EU). A final decision from the EC is expected within 67 days of receiving the CHMP opinion and will be applicable to the 27 EU member states, plus Iceland, Norway and Liechtenstein. It should be noted that ZTALMY has previously been approved by the FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older.
Marinus Pharmaceuticals Inc. (MRNS) Stock Analysis: Positive Earnings Growth Last Year But Negative This Year, 66.03% Revenue Growth And Outperforming Other Pharma Companies
On May 26, 2023, Marinus Pharmaceuticals Inc. (MRNS) had a previous close of $7.68 and an open of $7.70. The range for the day was between $7.00 and $7.70, with a volume of 775,574 shares traded. The market cap of MRNS was $410.4 million.
MRNS posted positive earnings growth of 81.16% last year, but earnings growth this year was negative at -477.03%. Expected earnings growth for the next five years is -10.00%. However, the company recorded revenue growth of 66.03% last year.
The P/E ratio for MRNS was not available (NM) at the time of writing the report, but the price to sales ratio was 6.10 and the price to book ratio was 3.60.
MRNS outperformed other pharmaceutical companies in the health technology sector.
The next report date for the MRNS is August 10, 2023 and the EPS forecast for this quarter is -$0.72.
Investors should continue to monitor the company’s financial performance and future earnings reports.
Marinus Pharmaceuticals Inc (MRNS) Stock Soars With Positive Future Outlook: Analysts Predict 220.06% Rise
On May 26, 2023, Marinus Pharmaceuticals Inc (MRNS) experienced an increase in stock performance. This is due to the company’s positive outlook for the future, as indicated by the 10 analysts offering 12-month price predictions. These analysts have a median target of 22.50, with a high estimate of 42.00 and a low estimate of 14.00. The middle estimate represents an increase of +220.06% from the last price of 7.03.